Table 4 MMR-D cases, their PD-L1 expression status and other pathologic characteristics
MMR-D status | Patient age (year-old) | Tumor PD-L1 | Peritumoral inflammation | Peritumoral inflammatory PD-L1 | Pathologic stage(FIGO) |
|---|---|---|---|---|---|
OCCC, MSH2/6 loss | 46 | Negative (< 1%) | > 50% | 5–10% | I |
OCCC, MSH2/6 loss | 44 | > 50% (extensive) | 50% | 10–50% | III |
OCCC, MSH2/6 loss | 35 | 11–25% | 5% | Negative (< 5%) | I |
OCCC, MLH1/PMS2 loss | 57 | 1–5% | 40% | > 50% | I |
ECCC, MSH2/6 loss | 35 | 11–25% | > 50% | > 50% | III |